Posts

ADC Therapeutics cuts 17% of staff after 27 patient deaths in Zynlonta trial

on

FDA Accepts sBLA for Roche's Lunsumio VELO and Polivy Combination in Relapsed or Refractory Large B-Cell Lymphoma

on

ADC Therapeutics shares sink over 50% after Phase 3 Zynlonta trial shows more deaths than standard therapy

on

Genmab and AbbVie's Epcoritamab Misses Overall Survival Endpoint but Meets PFS in Phase 3 DLBCL Trial

on

FDA Rejects Roche’s Columvi for Earlier-Line Diffuse Large B-Cell Lymphoma

on

Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review

on

FDA Approves Pfizer's Adcetris Combination Therapy for Relapsed/Refractory Large B-cell Lymphoma

on